Arnon Rosenthal, Ph.D., is the co-founder and CEO of Alector, a biotechnology company focused on developing therapies for neurodegenerative diseases. Since its inception in 2013, Rosenthal has been instrumental in steering Alector's strategic direction and scientific advancements. His extensive experience in the biotech industry includes co-founding Annexon Biosciences and Rinat Neuroscience Corporation, contributing significantly to the development of groundbreaking treatments.
Arnon Rosenthal's Email & LinkedIn
You can also contact Arnon Rosenthal through his LinkedIn.
If you want to find further information about Arnon Rosenthal, like his phone number, or other people working at Alector, sign up to Clay.
Who is the CEO of Alector?
Rosenthal has a rich history of pioneering work in the biotech industry. He co-founded Annexon Biosciences and Rinat Neuroscience Corporation, where he played pivotal roles in developing therapies for neurodegenerative diseases and cancer. His tenure at Genentech saw significant contributions, including the discovery of the target for the cancer drug Erivedge.
Since 2013, Rosenthal has been at the helm of Alector, driving its mission to develop transformative medicines for neurodegenerative diseases.
Work History
Arnon Rosenthal, Ph.D., has an impressive work history in the biotechnology sector. Here are the key positions he has held over the years:
- Genentech - Research Scientist (1990 to 2000)
- Rinat Neuroscience Corporation - Co-founder and Chief Scientific Officer (2001 to 2006)
- Annexon Biosciences - Co-founder and Chief Scientific Officer (2007 to 2012)
- Alector - Co-founder and CEO (2013 to Present)
Education History
Arnon Rosenthal, Ph.D., has a robust educational background that laid the foundation for his illustrious career in biotechnology. He earned his Ph.D. in Biology from the Hebrew University of Jerusalem, where he developed a deep understanding of biological sciences. This academic achievement was pivotal in shaping his future endeavors, providing him with the knowledge and skills necessary to co-found and lead several biotech companies, including Alector, Annexon Pharmaceuticals, and Rinat Neuroscience. His education has been instrumental in his ability to drive scientific innovation and develop transformative therapies for neurodegenerative diseases and cancer.
When did Arnon Rosenthal PhD join Alector?
Arnon Rosenthal, Ph.D., co-founded Alector in 2013. Since its inception, he has served as the Chief Executive Officer, guiding the company through its mission to develop transformative medicines for neurodegenerative diseases. With a Ph.D. in Biology from the Hebrew University of Jerusalem, Rosenthal has leveraged his extensive expertise to drive Alector's strategic direction and scientific advancements. As of 2024, he has been with Alector for approximately 11 years, playing a pivotal role in its growth and success.